Apogee Therapeutics, Inc.
APGE
Clasificación en acciones
#2366
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its... Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
Precio por acción
$135.07
Última sincronización: 2026-09-04
Capitalización bursátil
$8.36B
Cambio (1 día)
0.00%
Cambio (1 año)
137.21%
País
US
Comercio Apogee Therapeutics, Inc. (APGE)
Categoría
Healthcare
Ratio P/B de Apogee Therapeutics, Inc. (APGE)
Ratio P/B al October 2026 TTM: 8.53
Según los informes financieros más recientes y el precio de las acciones de Apogee Therapeutics, Inc., el ratio P/B actual (TTM) es 8.53. Al final de 2023, el ratio P/B era 3.73.
Historial del ratio P/B de Apogee Therapeutics, Inc. desde 2022 hasta 2026
Ratio P/B al final de cada año
| Año | Ratio P/B | Cambiar |
|---|---|---|
| 2026 (TTM) | 8.53 | 144.42% |
| 2024 | 3.49 | -6.37% |
| 2023 | 3.73 | -50.80% |
| 2022 | 7.57 | 0.00% |
Ratio P/B de empresas similares o competidoras
| Empresa | Ratio P/B | Diferencia del ratio P/B | País |
|---|---|---|---|
| 6.251 | -26.72% |
US
|
|
| 13.2547 | 55.39% |
US
|
|
| 4.208 | -50.67% |
AU
|
|
| - | - |
CH
|
|
| 6.1824 | -27.52% |
NL
|
